false
0001786511
00-0000000
0001786511
2023-12-08
2023-12-08
0001786511
FRES:AmericanDepositarySharesEachRepresenting20ClassOrdinarySharesParValueUs0.01PerShareMember
2023-12-08
2023-12-08
0001786511
FRES:ClassOrdinaryShareParValueUs0.01PerShareMember
2023-12-08
2023-12-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 8, 2023
Fresh2 Group Limited |
(Exact name of registrant as specified in its charter) |
British Virgin Islands |
|
001-39137 |
|
Not Applicable |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
650 5TH AVE STE 2416
NEW YORK,
United States |
|
NY 10019-6108 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: 917-397-6890
Not Applicable |
(Former name or former address, if changed since last report) |
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
American depositary shares (each representing 20 Class A ordinary shares, par value US$0.01 per share) |
|
FRES |
|
Nasdaq Capital Market |
Class A ordinary share, par value US$0.01 per share |
|
|
|
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a Material Definitive Agreement.
Amendment to the December 2022/January 2023 Agreements
As previously reported, in December 2022 and January 2023, Fresh2 Group
Limited (the “Company”) entered into investment agreements with several third party investors, whereby the investors purchased
29,714,279 newly issued Class A ordinary shares (1,485,714 American Depositary Shares or “ADSs”) of the Company at a price
of $0.175 per ordinary share or $3.50 per ADS (1:20 ADS-to-share ratio), for a total purchase price of $5.2 million. For each Class A
ordinary share purchased, the investors were to receive two warrants with each warrant to purchase one Class A ordinary share at an exercise
price of $0.21 per ordinary share (2,971,428 ADS an at exercise price of $4.20 per ADS). The warrants were to be exercisable within
2 years from the date of issuance. On March 8, 2023, two additional third-party investors invested an additional $205,000 under the same
terms (collectively referred to as the “Transactions”).
From December 2023 to March 2024, the Company entered into an Amendment
to Share Purchase Agreement (the “Amendment No.1”) and a Supplemental Agreement (the “Supplemental Agreement No.1”)
with each of the investors of the Transactions, whereby the Company agreed to issue an additional 46,328,557 Class A ordinary shares to
the investors and the investors agreed to terminate their rights to receive the warrants. As of the effective date of the Amendments and
the Supplemental Agreements, the Company had not issued any warrants to the investors. As of March 19, 2024, the Company had issued all
of the additional 46,328,557 Class A ordinary shares to the investors.
The foregoing description of
the Amendment No.1 and the Supplemental Agreement No. 1 does not purport to be complete and is qualified in its entirety by reference
to the agreements, the forms of which are filed as Exhibit 10.1 and Exhibit 10.2 hereto and are incorporated herein by reference.
Amendment to the June 2023 Agreement
As previously reported, June 2, 2023, the Company entered into an agreement
with Applegreen LLC (“Applegreen”), under which Applegreen agreed to purchase 22,000,000 Class A ordinary shares and warrants
to purchase 22,000,000 Class A ordinary shares at an aggregate purchase price of US$4.4 million. The warrants are exercisable within 2
years from the date of issuance and have an exercise price of US$4.20. The transaction closed on June 2, 2023 with Applegreen purchasing
19,500,000 Class A ordinary shares and warrants to purchase 19,500,000 Class A ordinary shares for $3.9 million. After the closing, Applegreen
transferred the aforesaid shares and warrants to two individual investors, Qin Hong and Danni Zhang.
On March 13, 2024, the Company entered into an amendment to the Applegreen
agreement (the “Amendment No.2”) and a Supplemental Agreement (the “Supplemental Agreement No.2”), as well as
a Share Purchase Agreement with each of the two investors (the “Share Purchase Agreement”), whereby the Company agreed to
issue an additional 91,928,571 Class A ordinary shares to the two investors and the two investors agreed to terminate their rights to
receive the warrants. On March 19, 2024, the Company issued the additional 91,928,571 Class A ordinary shares to the two investors. As
a result, Qin Hong and Danni Zhang acquired 40,000,000 and 71,428,571 shares of the Company, respectively.
The foregoing description of
the Amendment No.2, the Supplemental Agreement No.2, and the Share Purchase Agreements does not purport to be complete and is qualified
in its entirety by reference to the agreements, the forms of which are filed as Exhibit 10.3, Exhibit 10.4, Exhibit 10.5 and Exhibit 10.6
hereto and are incorporated herein by reference.
Item 3.02.
Unregistered sales of equity securities.
The disclosure set forth in Item 1.01 above is incorporated herein
by reference.
Item 9.01. Financial Statement and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 25, 2024 |
Fresh2 Group Limited |
|
|
|
By: |
/s/ Haohan Xu |
|
Name: |
Haohan Xu |
|
Title: |
Chief Executive Officer |
2
Exhibit 10.1
AMENDMENT TO SHARE
PURCHASE AGREEMENT
Amendment to the Share Purchase
Agreement, dated as of [*], 2024 (this “Amendment”), is entered into by and among Fresh2 Group Limited (the
“Company”), and [*] (the “Investor”) (each a “Party” and together
with the Company, the “Parties”).
WHEREAS, the Company and Investor
have entered into that certain share purchase agreement (the “Share Purchase Agreement”);
WHEREAS, the Parties hereto
desire to amend the Share Purchase Agreement on the terms and subject to the conditions set forth herein and in the Share Purchase Agreement;
and
NOW, THEREFORE, the Parties
agree as follows:
1.
Definitions. Capitalized terms used and not defined in this Amendment have the respective meanings assigned to them in
the Share Purchase Agreement.
2.
Amendments to the Share Purchase Agreement. As of the date first written above (the “Effective Date”),
the Share Purchase Agreement is hereby amended as follows:
(a) Paragraph A is hereby deleted
in its entirety and replaced with the following:
“A. The Company wishes
to sell to the Investor, and the Investor wishes to purchase, on the terms and subject to the conditions set forth in this Agreement,
ordinary shares. The share purchasing price shall be $0.07 per share ($1.4 per ADS), and the purchased shares shall collectively be referred
to herein as the “Securities”. The Investor will invest USD$[*] in the Company to acquire an aggregate number of 7,142,855
class A ordinary shares.”
(b) Section 1.1 is hereby deleted
in its entirety and replaced with the following:
1.1 Share Closing. Upon
the terms and subject to the satisfaction or waiver of the conditions set forth herein, the Company agrees to sell and the Investor agrees
to purchase the Securities for an aggregate purchase price of US$[*] (the “Share Purchase Price”). The Investor shall wire
investment fund to the Company designated bank account (per the Company’s wiring instruction in Exhibition A) within five business
days after effectiveness of this Agreement. The date on which the closing of each purchase and sale of shares occurs (the “Share
Closing”) is hereinafter referred to as the “Share Closing Date”. The Share Closing of the purchase of [*] Class A
Ordinary Shares will be deemed to occur when (A) this Agreement has been executed and delivered by the Company and the Investor, (B)
each of the conditions to the Share Closing described in Section 5 of this Agreement has been satisfied or waived as specified therein
and (C) full payment of the Share Purchase Price has been made by the Investor to the Company by wire transfer of immediately available
funds against physical delivery by the Company of duly executed certificates representing the securities being purchased by the Investor,
registered in the name and address of the Investor as is set forth on the signature page hereto. The Share Closing of the purchase of
[*] Class A Ordinary Shares shall be within 3 days after the date of this Amendment
(c) Section 5.1.2 is hereby deleted
in its entirety and replaced with the following:
“5.1.2 After receiving
the full amount of the Share Purchase Price wired to the Company Bank account, the Company shall send to CITI bank N.A. as the Depositary,
Maples Fund Services (Cayman) Limited as the Registrar, orders to issue to the Investor [*] class A ordinary shares and [*] class A ordinary
shares at their respective Share Closing Date in accordance with Section 1.1.”
3. Date
of Effectiveness; Limited Effect. This Amendment will become effective on the date first written above. Except as expressly
provided in this Amendment or any other agreements between the parties, all of the terms and provisions of the Share Purchase Agreement
are and will remain in full force and effect and are hereby ratified and confirmed by the Parties. Without limiting the generality of
the foregoing, the amendments contained herein will not be construed as an amendment to or waiver of any other provision of the Share
Purchase Agreement or as a waiver of or consent to any further or future action on the part of either Party that would require the waiver
or consent of the other Party. On and after the Effective Date, each reference in the Share Purchase Agreement to “this Agreement,”
“the Agreement,” “hereunder,” “hereof,” “herein,” or words of like import, and each reference
to the Share Purchase Agreement in any other agreements, documents, or instruments executed and delivered pursuant to, or in connection
with, the Share Purchase Agreement, will mean and be a reference to the Share Purchase Agreement as amended by this Amendment.
4.
Miscellaneous.
(a) This Amendment is governed
by, and construed in accordance with, the laws of the State of New York, without regard to the conflict of laws provisions of such state.
(b) This Amendment shall inure
to the benefit of and be binding upon each of the Parties and each of their respective permitted successors and permitted assigns.
(c) The headings in this Amendment
are for reference only and do not affect the interpretation of this Amendment.
(d) This Amendment may be executed
in several counterparts, each of which shall be deemed an original but all of which shall constitute one and the same instrument. Counterparts
may be delivered by any electronic signature and any counterpart so delivered shall be deemed to have been duly and validly delivered
and be valid and effective for all purposes.
(e) This Amendment constitutes
the sole and entire agreement between the Parties with respect to the subject matter contained herein, and supersedes all prior and contemporaneous
understandings, agreements, representations, and warranties, both written and oral, with respect to such subject matter.
[Signature page follows]
IN WITNESS WHEREOF, the Parties
have executed this Amendment to the Share Purchase Agreement as of the date first written above.
[INVESTOR] |
|
Fresh2 Group Limited |
|
|
|
By: |
|
|
By: |
|
Name: |
|
|
Name: |
Haohan Xu |
Title: |
|
|
Title: |
CEO |
[Signature Page to Amendment to the Share Purchase Agreement]
3
Exhibit 10.2
SUPPLEMENTAL
AGREEMENT
This
supplemental agreement (the “Supplemental Agreement”) is made and entered into as of [*] (the “Effective
Date”), between Fresh2 Group Limited (the “Company”), and ***INC (the “Investor”) (Each, “Party”,
or collectively, “Parties”).
WHEREAS,
the Parties entered into that certain Share Purchase Agreement dated as of [*] (the “Purchase Agreement”);
WHEREAS,
the Parties entered into that certain Amendment to Share Purchase Agreement dated as of [*] (the “Amendment”);
WHEREAS,
According to the Purchase Agreement, the Investor shall receive from the Company [*] warrants of the Company (“Warrants”),
and according to the Amendment, the Investor shall purchase [*] class A ordinary shares of the Company (“Purchased Shares”).
NOW,
THEREFORE, in consideration of the foregoing promises and the mutual covenants contained herein, the Parties, intending to be legally
bound, agree as follows:
| 1. | All
the Parties agree that all the rights of the Investor to receive Warrants from the Company
are forfeited and terminated as of the Effective Date and, as a result of such termination,
all the Parties hereby acknowledge and agree that the Company shall have no further liability
to the Investor to issue or exercise any Warrants, and none of the Parties shall have the
right to seek any remedies to any other Parties with respect to Warrants under the Purchase
Agreement. |
| 2. | All
the Parties acknowledge and agree that the Company has issued to the Investor [*] Class A
ordinary shares of the Company prior to the Effective Date under the Purchase Agreement and
the Amendment, and the Company shall issue [*] Class A ordinary shares of the Company (“Second
Tranche Shares”) to the Investor at its Share Closing Date in accordance with the Amendment.
The Investor shall not transfer any Second Tranche Shares or convert any Second Tranche Shares
to ADS of the Company, except that, subject to applicable laws, the Investor (i) may transfer
50% Second Tranche Shares or convert such 50% Second Tranche Shares to ADS of the Company
on or after the 180th day after the Effective Date, and (ii) may transfer the
remaining 50% Second Tranche Shares or convert such 50% Second Tranche Shares to ADS on or
after the first anniversary of the Effective Date. |
| 3. | Jurisdiction.
This Supplemental Agreement and all questions regarding its existence, validity, interpretation,
breach or performance of this Supplemental Agreement, shall be governed by, and construed
and enforced in accordance with, the laws of the State of New York. Any dispute shall be
finally settled by litigation brought solely in a Federal Court or state court located in
the State of New York, and the Parties hereby submit to the exclusive jurisdiction of such
courts. |
| 4. | Counterparts.
This Supplemental Agreement may be executed in counterparts, each of which shall be deemed
an original, but such counterparts, when taken together, shall constitute one agreement. |
| 5. | Binding
Effect. This Supplemental Agreement shall inure to the benefit of, and shall be binding
upon, the Parties hereto and their respective legal representatives, successors and assigns. |
| 6. | Further
Assurances. Each of the Parties hereby agrees to execute such further documents or instruments
as may be necessary or appropriate to carry out the intention of this Supplemental Agreement. |
IN WITNESS WHEREOF,
the Parties have executed this Supplemental Agreement as of the Effective Date.
|
Fresh2 Group Limited |
|
|
|
By: |
|
|
Name: |
Haohan Xu |
|
Title: |
CEO |
|
|
|
[INVESTOR] |
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
Exhibit 10.3
AMENDMENT TO SHARE PURCHASE AGREEMENT
Amendment to the Share Purchase
Agreement, dated as of February 20, 2024 (this “Amendment”), is entered into by and among Fresh2 Group Limited
(the “Company”), and Applegreen LLC (the “Investor”) (each a “Party”
and together with the Company, the “Parties”).
WHEREAS, the Company and Investor
have entered into that certain share purchase agreement on June 2, 2023 (the “Share Purchase Agreement”);
WHEREAS, the Parties hereto
desire to amend the Share Purchase Agreement on the terms and subject to the conditions set forth herein and in the Share Purchase Agreement;
and
NOW, THEREFORE, the Parties
agree as follows:
1.
Definitions. Capitalized terms used and not defined in this Amendment have
the respective meanings assigned to them in the Share Purchase Agreement.
2. Amendments
to the Share Purchase Agreement. As of the date first written above (the “Effective
Date”), the Share Purchase Agreement is hereby amended as follows:
(a) Paragraph
A is hereby deleted in its entirety and replaced with the following:
“A. The Company
wishes to sell to the Investor, and the Investor wishes to purchase, on the terms and subject to the conditions set forth in this
Agreement, ordinary shares. The share purchasing price shall be $0.035 per share ($0.7 per ADS), and the purchased shares shall
collectively be referred to herein as the “Securities”. The Investor will invest USD$3,900,000 in the Company to acquire
an aggregate number of 111,428,571 class A ordinary shares.”
3. Date
of Effectiveness; Limited Effect. This Amendment will become effective on the date first written above. Except as expressly
provided in this Amendment or any other agreements between the parties, all of the terms and provisions of the Share Purchase Agreement
are and will remain in full force and effect and are hereby ratified and confirmed by the Parties. Without limiting the generality of
the foregoing, the amendments contained herein will not be construed as an amendment to or waiver of any other provision of the Share
Purchase Agreement or as a waiver of or consent to any further or future action on the part of either Party that would require the waiver
or consent of the other Party. On and after the Effective Date, each reference in the Share Purchase Agreement to “this Agreement,”
“the Agreement,” “hereunder,” “hereof,” “herein,” or words of like import, and each reference
to the Share Purchase Agreement in any other agreements, documents, or instruments executed and delivered pursuant to, or in connection
with, the Share Purchase Agreement, will mean and be a reference to the Share Purchase Agreement as amended by this Amendment.
4.
Miscellaneous.
(a) This
Amendment is governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflict of laws
provisions of such state.
(b) This
Amendment shall inure to the benefit of and be binding upon each of the Parties and each of their respective permitted successors and
permitted assigns.
(c) The
headings in this Amendment are for reference only and do not affect the interpretation of this Amendment.
(d) This
Amendment may be executed in several counterparts, each of which shall be deemed an original but all of which shall constitute one and
the same instrument. Counterparts may be delivered by any electronic signature and any counterpart so delivered shall be deemed to have
been duly and validly delivered and be valid and effective for all purposes.
(e) This
Amendment constitutes the sole and entire agreement between the Parties with respect to the subject matter contained herein, and supersedes
all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, with respect to such
subject matter.
[Signature page follows]
IN WITNESS WHEREOF, the Parties
have executed this Amendment to the Share Purchase Agreement as of the date first written above.
Applegreen LLC |
|
Fresh2 Group Limited |
|
|
|
By: |
/s/ Qin Hong |
|
By: |
/s/ Haohan Xu |
Name: |
Qin Hong |
|
Name: |
Haohan Xu |
Title: |
|
|
Title: |
CEO |
|
|
Date: |
March 13, 2024 |
[Signature Page to Amendment to the Share Purchase Agreement]
Exhibit 10.4
SUPPLEMENTAL AGREEMENT
This
supplemental agreement (the “Supplemental Agreement”) is made and entered into as of February 20, 2024 (the “Effective
Date”), between Fresh2 Group Limited (formerly, “AnPac Bio-Medical Science Co., Ltd.”) (the “Company”),
and Applegreen LLC (the “Investor”) (Each, “Party”, or collectively, “Parties”).
WHEREAS,
the Parties entered into that certain Share Purchase Agreement dated as of June 2, 2023 (the “Purchase Agreement”);
WHEREAS,
the Parties entered into that certain Amendment to Share Purchase Agreement dated as of Feburay 20, 2024 (the “Amendment”);
WHEREAS,
According to the Purchase Agreement, the Investor has received from the Company 22,000,000 Warrants of the Company, as defined in the
Purchase Agreement (“Warrants”);
NOW,
THEREFORE, in consideration of the foregoing promises and the mutual covenants contained herein, the Parties, intending to be legally
bound, agree as follows:
| 1. | All the Parties agree that all the Warrants issued to the
Investor shall be canceled and terminated, and all the rights of the Investor to receive any ordinary shares from the Company under the
Warrants are forfeited and terminated as of the Effective Date and, as a result of such termination, all the Parties hereby acknowledge
and agree that the Company shall have no further liability to the Investor to issue or exercise any Warrants, and none of the Parties
shall have the right to seek any remedies to any other Parties with respect to issuance or exercise of Warrants. All the Parties agree
that all the rights of the Investor to receive any other warrants from the Company that are not issued to the Investor as of the Effective
Date, if any, under the Purchase Agreement are forfeited and terminated as of the Effective Date. |
| 2. | All the Parties agree that besides the Share Purchase Price
paid by the Investor in accordance with the Purchase Agreement and Amendment, the $1,155,000 paid by the Investor to the Company prior
to Effective Date shall be the consideration for the purchase of the 33,000,000 Class A Ordinary Shares by Qin Hong. the $ 2,062,500
paid by the Investor to the Company prior to Effective Date shall be the consideration for the purchase of the 58,928,571 Class A Ordinary
Shares by Danni Zhang. |
| 3. | Jurisdiction. This Supplemental Agreement and all
questions regarding its existence, validity, interpretation, breach or performance of this Supplemental Agreement, shall be governed
by, and construed and enforced in accordance with, the laws of the State of New York. Any dispute shall be finally settled by litigation
brought solely in a Federal Court or state court located in the State of New York, and the Parties hereby submit to the exclusive jurisdiction
of such courts. |
| 4. | Counterparts. This Supplemental Agreement may be executed
in counterparts, each of which shall be deemed an original, but such counterparts, when taken together, shall constitute one agreement. |
| 5. | Binding Effect. This Supplemental Agreement shall
inure to the benefit of, and shall be binding upon, the Parties hereto and their respective legal representatives, successors and assigns. |
| 6. | Further Assurances. Each of the Parties hereby agrees
to execute such further documents or instruments as may be necessary or appropriate to carry out the intention of this Supplemental Agreement. |
IN WITNESS WHEREOF,
the Parties have executed this Supplemental Agreement as of the Effective Date.
|
Fresh2 Group Limited |
|
|
|
|
By: |
/s/ Haohan Xu |
|
Name: |
Haohan Xu |
|
Title: |
CEO |
|
Date: |
March 13, 2024 |
|
Applegreen LLC |
|
|
|
|
By: |
/s/ Qin Hong |
|
Name: |
Qin Hong |
|
Title: |
|
Exhibit 10.5
SHARES PURCHASE AGREEMENT
SHARES PURCHASE AGREEMENT
(this “Agreement”), dated as of February 20, 2024, by and between Fresh2 Group Limited, a British Virgin Islands
corporation (the “Company”), and Hong Qin (the “Investor”).
A.
The Company wishes to sell to the Investor, and the Investor wishes to purchase, on the terms and subject to the conditions set
forth in this Agreement, ordinary shares of the Company. The share purchasing price shall be $0.035 per share, and the purchased shares
shall collectively be referred to herein as the “Securities”.
B.
The sale of the Securities by the Company to the Investor will be effected in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) under the Securities Act.
In consideration of the mutual
promises made herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company
and the Investor hereby agree as follows:
| 1. | PURCHASE AND SALE OF THE SECURITIES. |
1.1 Share Closing.
Upon the terms and subject to the satisfaction or waiver of the conditions set forth herein, the Company agrees to sell and the Investor
agrees to purchase the Securities for an aggregate purchase price of US$ 1,155,000 (the “Share Purchase Price”).
The date on which the closing of such purchase and sale occurs (the “Share Closing”) is hereinafter referred to as the “Share
Closing Date”. The Share Closing will be deemed to occur when (A) this Agreement has been executed and delivered by the Company
and the Investor, (B) each of the conditions to the Share Closing described in Section 5 of this Agreement has been satisfied
or waived as specified therein and (C) full payment of the Share Purchase Price has been made by the Investor or another person agreed
by the Company to the Company by wire transfer of immediately available funds. All the parties acknowledge that the Share Purchase Price
has been paid prior to the Share Closing Date by Applegreen LLC to the Company.
1.2 Certain Definitions.
When used herein, the following terms shall have the respective meanings indicated:
“Affiliate”
means, as to a specified Person, a Person that directly, or indirectly through one or more intermediaries, controls, or is controlled
by, or is under common control with, the specified Person. For the purposes of this definition, “control” (including
the terms “controlling” “controlled by” and “under common control with”) means the possession, direct
or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of
voting securities, by contract or otherwise.
“ADSs” refers to
our American depositary shares, each of which represents twenty Class A ordinary shares.
“Board of Directors”
means the Company’s board of directors.
“Business Day”
means any day other than a Saturday, a Sunday or a day on which The NASDAQ Stock Market is closed or on which banks in The City of New
York are required or authorized by law to be closed.
“Closing”
means each of the Share Closing.
“Closing Date”
means each of the Share Closing Date
“Commission”
means the Securities and Exchange Commission.
“Governmental Authority”
means any nation or government, any state, provincial or political subdivision thereof having jurisdiction over the Company and any entity
exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including without
limitation any stock exchange, securities market or self-regulatory organization.
“Law”
means any applicable federal, state, local or foreign or provincial law, statute, code, ordinance, rule, regulation, judgment,
order, injunction, decree or agency requirement of or undertaking to or agreement with any Governmental Authority, including common law.
“Material Adverse
Effect” means, with respect to any Person, any fact, circumstance, event, change, effect or occurrence that, individually
or in the aggregate with all other facts, circumstances, events, changes, effects or occurrences (i) has or would be reasonably expected
to have a material adverse effect on or with respect to the business, results of operation or financial condition of such Person and its
Subsidiaries, if any, taken as a whole, or (ii) that prevents or materially delays or materially impairs the ability of such Person to
consummate the transactions contemplated by this Agreement.
“NASDAQ”
means the NASDAQ Stock Market.
“Person”
means any individual, corporation, trust, association, company, partnership, joint venture, limited liability company, joint stock company,
Governmental Authority or other entity.
“Rule 506”
means Rule 506 promulgated under Regulation D under the Securities Act or any successor provision.
“SEC Reports”
means (i) the Form 20-F filed by the Company, and (ii) each form, document, statement and report filed by the Company since September
20, 2019.
“Securities”
has the meaning specified in the preamble to this Agreement.
“Securities Act”
means the Securities Act of 1933, as amended (or any successor act), and the rules and regulations thereunder (or respective successors
thereto).
“Share Closing”
has the meaning specified in Section 1.1 of this Agreement.
“Share Closing Date”
has the meaning specified in Section 1.1 of this Agreement.
“Share Purchase
Price” has the meaning specified in Section 1.1 of this Agreement.
1.3 Other Definitional
Provisions. All definitions contained in this Agreement are equally applicable to the singular and plural forms of the terms defined.
The words “hereof”, “herein” and “hereunder” and words
of similar import referring to this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement.
| 2. | REPRESENTATIONS AND WARRANTIES OF THE INVESTOR. |
The Investor hereby represents
and warrants to the Company and agrees with the Company, that, as of the date hereof:
2.1 Enforceability.
The Investor has the requisite power and authority to purchase the Securities to be purchased by him hereunder and to execute, deliver
and perform its obligations pursuant to this Agreement. This Agreement constitutes, upon execution and delivery thereof, the Investor’s
valid and legally binding obligation, enforceable in accordance with its terms, subject to (i) applicable bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium or other similar laws of general application relating to or affecting the enforcement of creditors’
rights generally and (ii) general principles of equity.
2.2 Investor Status.
At the time the Investor was offered the Securities, the Investor was and at the date hereof, is (i) an “accredited investor”
as defined in Rule 501 of Regulation D under the Securities Act and (ii) not formed or organized with the specific purpose of making
an investment in the Company. The Investor’s financial condition is such that he is able to bear the risk of holding the Securities
for an indefinite period of time and the risk of loss of his entire investment. The Investor has such knowledge and experience in business
and financial matters so as to enable it to understand the risks of and form an investment decision with respect to his investment in
the Securities.
2.3 Disqualification.
The Investor represents that neither the Investor, nor any person or entity with whom the Investor shares beneficial ownership of Company
securities, is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities
Act. Investor also agrees to notify the Company if Investor or any person or entity with whom Investor or any person or entity with whom
Investor shares beneficial ownership of Company securities becomes subject to such disqualifications after the date hereof (so long as
Investor or any such person beneficially owns any equity securities of the Company).
2.4 Purchase Entirely for
Own Account. The Investor is acquiring the Securities for his own account and not with a view to, or for sale in connection with,
any distribution of the Securities in violation of the Securities Act. The Investor has no present agreement, undertaking, arrangement,
obligation or commitment providing for the disposition of the Securities.
2.5 Information. The
Investor acknowledges that he has been provided with information regarding the business, operations and financial condition of the Company
and has, prior to the date hereof, been granted the opportunity to ask questions of and receive answers from representatives of the Company,
its officers, directors, employees and agents concerning the Company in order for the Investor to make an informed decision with respect
to his investment in the Securities. The Investor has sought such accounting, legal and tax advice as well as language translation since
this agreement is written in English as he deems appropriate in connection with his proposed investment in the Securities.
2.6 Securities Not Registered
in the United States. The Investor understands that the Securities have not been registered under the Securities Act, by reason of
their issuance by the Company in a transaction exempt from the registration requirements of the Securities Act, and that the Securities
must continue to be held by the Investor until a subsequent disposition thereof is registered under the Securities Act, including pursuant
to the Registration Statement, or is exempt from such registration.
2.7 Reliance on Exemptions.
The Investor understands that the Securities are being offered and sold to him in reliance upon specific exemptions from the registration
requirements of U.S. federal and state securities laws and that the Company is relying upon the truth and accuracy of the representations
and warranties of the Investor set forth in this Section 2 in order to determine the availability of such exemptions and the eligibility
of the Investor to acquire the Securities.
2.8 Securities
Ownership. The Investor’s investment in the Securities is not for the purpose of acquiring, directly or indirectly,
control of, and they have no intent to acquire or exercise control of, the Company.
2.9 Investor’s Financing.
At the Closing, the Investor will have all funds necessary to pay to the Company the Share Purchase Price for the Securities being purchased
by the Investor hereby in immediately available funds.
2.10 Brokers. The Investor
has not retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement
whose fees the Company would be required to pay.
2.11 No Governmental Review.
The Investor understands that no Governmental Authority has passed on or made any recommendation or endorsement of the Securities or
the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering
of the Securities.
2.12 No General Solicitation.
The Investor is not purchasing the Securities as a result of any advertisement, article, notice or other communication published in a
newspaper or magazine or similar media or broadcast over television or radio, whether closed circuit, or generally available, or any
seminar, meeting or other conference whose attendees were invited by any general solicitation or general advertising.
2.13 Reliance on Information.
The Investor has, in connection with the Investor’s decision to purchase the Securities, not relied upon any representations or
other information (whether oral or written) other than as set forth in the representations and warranties of the Company contained herein
and in the SEC Reports, and the Investor has, with respect to all matters relating to this Agreement and the offer and sale of the Securities,
relied solely upon the advice of the Investor’s own counsel and has not relied upon or consulted counsel of the Company.
| 3. | REPRESENTATIONS AND WARRANTIES OF THE COMPANY. |
The Company hereby represents and warrants
to the Investor and agrees with the Investor that, as of the date hereof:
3.1 Organization, Good
Standing and Qualification. The Company is duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization, with all requisite power and authority to carry on its business as now conducted. The Company is not in violation
of its certificate of incorporation, by-laws or other equivalent organizational or governing documents, except where the violation would
not, individually or in the aggregate, have a Material Adverse Effect.
3.2 Authorization; Consents.
The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement and to issue
and sell the Securities to the Investor in accordance with the terms hereof. All consents, approvals, orders and authorizations required
on the part of the Company in connection with the execution, delivery or performance of this Agreement have been obtained or made, other
than such consents, approvals, orders and authorizations the failure of which to make or obtain would not have a Material Adverse Effect.
3.3 Enforcement. This
Agreement has been duly executed and delivered by the Company. This Agreement constitutes the valid and legally binding obligation of
the Company, enforceable against it in accordance with its terms, subject to (i) applicable bankruptcy, insolvency, fraudulent transfer,
moratorium, reorganization or other similar laws of general application relating to or affecting the enforcement of creditors’
rights generally, (ii) general principles of equity and (iii) with respect to the enforcement of any rights to indemnity and contribution,
federal and state securities laws and principles of public policy.
3.4 Disqualification.
The Company is not disqualified from relying on Rule 506 for any of the reasons stated in Rule 506(d) in connection with the issuance
and sale of the Securities to the Investor.
3.5 Capitalization.
The capitalization of the Company, including its authorized capital stock, the number of shares issued and outstanding, the number of
shares issuable and reserved for issuance pursuant to the Company’s equity plans and agreements and the number of shares issuable
and reserved for issuance pursuant to securities exercisable for, or convertible into or exchangeable for any ADSs, is as set forth in
the SEC Reports. Other than as contemplated by this Agreement and as described in the SEC Reports, there are no options, warrants, calls,
rights, commitments, preemptive rights, rights of first refusal or other agreements to which the Company is a party or by which it is
bound obligating the Company to issue, deliver, sell, repurchase or redeem, or cause to be issued, delivered, sold, repurchased or redeemed,
any shares of the capital stock of the Company or obligating the Company to grant, extend or enter into any such option, warrant, call,
right, commitment or agreement. No preemptive right, co-sale right, right of first refusal or other similar right exists with respect
to the Securities or the issuance and sale thereof. No further approval or authorization of any stockholder, or the Board of Directors
is required for the issuance and sale of the Securities.
3.6 Due Authorization;
Valid Issuance. The Securities are duly authorized and, when issued in accordance with the terms of this Agreement, will be duly
and validly issued, fully paid and nonassessable, free of pre-emptive or similar rights and free and clear of all liens, encumbrances
and other restrictions (other than those arising under federal or state securities laws as a result of the private placement contemplated
hereby).
3.7 General Solicitation;
No Integration. Neither the Company nor any of its Affiliates, nor any person acting on its or their behalf, has engaged in a general
solicitation or general advertising (within the meaning of Regulation D) of investors with respect to offers or sales of the Securities.
3.8 Stockholder Consent.
No consent or approval of the stockholders of the Company is required or necessary for the Company to enter into this Agreement or to
consummate the transactions contemplated hereby and thereby.
| 4. | OTHER AGREEMENTS OF THE PARTIES. |
4.1 Transfer Restrictions.
(a) The Investor covenants
that the Securities will only be disposed of pursuant to an effective registration statement under, and in compliance with the
requirements of, the Securities Act or pursuant to an available exemption from the registration requirements of the Securities Act,
and in compliance with any applicable state securities laws, provided that, the Investor shall not transfer any Securities or
convert any Securities to ADS of the Company except that the Investor (i) may transfer 50% Securities or convert such 50% Securities
to ADS of the Company on or after the 180th day after the Share Closing Date, and (ii) may transfer the remaining 50% Securities or
convert such 50% Securities to ADS on or after the first anniversary of the Share Closing Date. In connection with any transfer of
Securities other than pursuant to an effective registration statement or to the Company, the Company may require the transferor to
provide to the Company an opinion of counsel selected by the transferor, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that such transfer does not require registration under the Securities Act.
(b) The Investor agrees to
the imprinting, so long as is required by this Section 4.1(b), of a legend on any certificate evidencing Securities
substantially to the following effect:
“THE SECURITIES REFERENCED
HEREIN HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”) AND
HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION
MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE U.S. SECURITIES ACT.”
5.1 Conditions to Investor’s
Obligations at the Closings. The Investor’s obligations to effect the Closing, including without limitation its obligation
to purchase the Securities at Closing, are conditioned upon the fulfillment (or waiver by the Investor in its sole and absolute discretion)
of each of the following events as of the Closing Date:
| 5.1.1 | the representations and warranties of the Company set forth in this Agreement shall be true and correct
in all material respects as of the Closing Date as if made on such date (except that to the extent that any such representation or warranty
relates to a particular date, such representation or warranty shall be true and correct in all material respects as of that particular
date); |
5.2 Conditions to Company’s
Obligations at the Closings. The Company’s obligations to effect the Closing with the Investor are conditioned upon the fulfillment
(or waiver by the Company in its sole and absolute discretion) of each of the following events as of the Closing Date:
| 5.2.1 | the representations and warranties of the Investor set forth in this Agreement shall be true and correct
in all material respects as of the Closing Date as if made on such date (except that to the extent that any such representation or warranty
relates to a particular date, such representation or warranty shall be true and correct in all material respects as of that date); |
| 5.2.2 | the Investor or another person agreed by the Company shall have tendered to the Company the Share Purchase
Price for the Securities being purchased by it at the Closing by wire transfer of immediately available funds. |
6.1 Termination. This
Agreement may be terminated by the Company or the Investor, by written notice to the other party, if the Closings have not been consummated
within five business days after effectiveness of this Agreement; provided that no such termination will affect the right of any party
to sue for any breach by the other party.
6.2 Liquidated Damages.
6.2.1 If (a) the Investor has completed its obligations under Sections 5.1.1 and 5.1.2, and has tendered the Share Purchase Price as required in Section 5.2.2, and (b) the Company fails to complete the obligations set forth in Section 5.1, then upon receipt of written or email request from the Investor, the Company shall promptly return to the Investor any cash deposit to the Company Bank Account made by the investor within 5 business days; the Investor is entitle to a penalty payment by the company to the Investor at the rate of 1% per day if the cash is not returned to the investor after the 5 business days post notification.
6.2.2 If (a) the Company has completed its obligations under Section 5.2.1 and has tendered the Securities as required in 5.1.2, and (b) the Investor fails to complete the obligations set forth in Section 5.2 or otherwise fails to consummate the transaction, then the Company shall have no obligation to issue the Securities.
The Company shall pay all expenses
incurred by the Investor enforcing of this Agreement including the Investor’s legal, litigation fees, court costs and expenses.
6.2.3
This Section 6.2 shall survive any termination or expiration of this Agreement.
6.3 Survival; Severability.
The covenants and indemnities, agreements, representations and warranties made by the parties herein shall survive the Closings, provided,
however, that the representations and warranties set forth or made by the Investor herein will terminate upon the final sale of the Securities.
In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable
or void, this Agreement shall continue in full force and effect without said provision; provided that in such case the parties
shall negotiate in good faith to replace such provision with a new provision which is not illegal, unenforceable or void, as long as
such new provision does not materially change the economic benefits of this Agreement to the parties.
6.4 Successors and Assigns.
The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted
assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement without the written
consent of the other party.
6.5 Remedies. In addition
to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Company and the
Investor will be entitled to seek specific performance under this Agreement. The parties agree that monetary damages may not be adequate
compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agrees to waive
in any action for specific performance of any such obligation (other than in connection with any action for temporary restraining order)
the defense that a remedy at law would be adequate.
6.6 Governing Law; Jurisdiction;
Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York. Each
party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York for the
adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby and hereby irrevocably waives,
and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding
is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law. Each party hereby waives all rights to a trial by jury.
6.7 Counterparts. This
Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute
one and the same instrument. This Agreement may be executed and delivered by facsimile transmission.
6.8 Headings. The headings
used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
6.9 Notices. Any notice,
demand or request required or permitted to be given by the Company or any Investor pursuant to the terms of this Agreement shall be in
writing and shall be deemed delivered (i) when delivered personally or by verifiable facsimile transmission, unless such delivery is
made on a day that is not a Business Day, in which case such delivery will be deemed to be made on the next succeeding Business Day,
(ii) on the next Business Day after timely delivery to an overnight courier and (iii) on the Business Day actually received if deposited
in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid), addressed as follows:
If to the Company:
Fresh2 Group Limited
Address: 650 5th AVE STE 2416
NEW YORK NY 10019
Email: shareholder@fresh2.co
Telephone: +1-9173976890
If to the Investor:
Hong Qin
Address: B5 YUAN YANG LA VIE, SUN HE KANG
YING DONG LU, CHAOYANG Beijing China
Email: [ ]
Telephone: [ ]
6.10
Fees and Expenses. The Company shall pay all expenses incurred incident to the negotiation, preparation, execution, delivery
and performance of this Agreement, including reasonable fees and expenses of the Investor’s legal advisers incurred on or prior
to the Closing Dates. The Company shall pay all stamp taxes and other taxes and duties levied in connection with the sale and issuance
of his Securities. Upon request by written or email notice from the Investor, the Company shall remove within 5 business days all the
legend of any certificate evidencing that the Security is registered, and all restriction written per section 4.1.a and 4.1.b removed;
the Company shall pay all expenses incurred to remove the legend and registered the Security.
6.11
Entire Agreement; Amendments. This Agreement constitutes the entire agreement between the parties with regard to the subject
matter hereof, superseding all prior agreements or understandings, whether written or oral, between or among the parties. Except as expressly
provided herein, neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company
and the Investor, and no provision hereof may be waived other than by a written instrument signed by the party against whom enforcement
of any such waiver is sought. Any waiver or consent shall be effective only in the specific instance and for the specific purpose for
which given.
[Signature Pages to Follow]
IN WITNESS WHEREOF, the undersigned
have duly executed this Securities Purchase Agreement as of the date first above written.
|
Fresh2 Group Limited |
|
|
|
|
By: |
/s/ Haohan Xu |
|
Name: |
Haohan Xu |
|
Title: |
Chairperson and Chief Executive Officer |
|
Date: |
March 13, 2024 |
|
|
|
|
INVESTOR |
|
|
|
|
Hong Qin |
|
|
|
/s/ Hong Qin |
11
Exhibit 10.6
SHARES PURCHASE AGREEMENT
SHARES PURCHASE AGREEMENT
(this “Agreement”), dated as of February 20, 2024, by and between Fresh2 Group Limited, a British Virgin Islands
corporation (the “Company”), and Danni Zhang (the “Investor”).
A.
The Company wishes to sell to the Investor, and the Investor wishes to purchase, on the terms and subject to the conditions set
forth in this Agreement, ordinary shares of the Company. The share purchasing price shall be $0.035 per share, and the purchased shares
shall collectively be referred to herein as the “Securities”.
B.
The sale of the Securities by the Company to the Investor will be effected in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) under the Securities Act.
In consideration of the mutual
promises made herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company
and the Investor hereby agree as follows:
| 1. | PURCHASE AND SALE OF THE SECURITIES. |
1.1
Share Closing. Upon the terms and subject to the satisfaction or waiver of the conditions set forth herein, the Company
agrees to sell and the Investor agrees to purchase the Securities for an aggregate purchase price of US$ 2,062,500 (the “Share
Purchase Price”). The date on which the closing of such purchase and sale occurs (the “Share Closing”) is hereinafter
referred to as the “Share Closing Date”. The Share Closing will be deemed to occur when (A) this Agreement has been executed
and delivered by the Company and the Investor, (B) each of the conditions to the Share Closing described in Section 5 of this Agreement
has been satisfied or waived as specified therein and (C) full payment of the Share Purchase Price has been made by the Investor or another
person agreed by the Company to the Company by wire transfer of immediately available funds. All the parties acknowledge that the Share
Purchase Price has been paid prior to the Share Closing Date by Applegreen LLC to the Company.
1.2
Certain Definitions. When used herein, the following terms shall have the respective meanings indicated:
“Affiliate”
means, as to a specified Person, a Person that directly, or indirectly through one or more intermediaries, controls, or is controlled
by, or is under common control with, the specified Person. For the purposes of this definition, “control” (including
the terms “controlling” “controlled by” and “under common control with”) means the possession, direct
or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of
voting securities, by contract or otherwise.
“ADSs” refers to
our American depositary shares, each of which represents twenty Class A ordinary shares.
“Board of Directors”
means the Company’s board of directors.
“Business Day”
means any day other than a Saturday, a Sunday or a day on which The NASDAQ Stock Market is closed or on which banks in The City of New
York are required or authorized by law to be closed.
“Closing”
means each of the Share Closing.
“Closing Date”
means each of the Share Closing Date
“Commission”
means the Securities and Exchange Commission.
“Governmental Authority”
means any nation or government, any state, provincial or political subdivision thereof having jurisdiction over the Company and any entity
exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including without
limitation any stock exchange, securities market or self-regulatory organization.
“Law”
means any applicable federal, state, local or foreign or provincial law, statute, code, ordinance, rule, regulation, judgment, order,
injunction, decree or agency requirement of or undertaking to or agreement with any Governmental Authority, including common law.
“Material Adverse
Effect” means, with respect to any Person, any fact, circumstance, event, change, effect or occurrence that, individually
or in the aggregate with all other facts, circumstances, events, changes, effects or occurrences (i) has or would be reasonably expected
to have a material adverse effect on or with respect to the business, results of operation or financial condition of such Person and its
Subsidiaries, if any, taken as a whole, or (ii) that prevents or materially delays or materially impairs the ability of such Person to
consummate the transactions contemplated by this Agreement.
“NASDAQ”
means the NASDAQ Stock Market.
“Person”
means any individual, corporation, trust, association, company, partnership, joint venture, limited liability company, joint stock company,
Governmental Authority or other entity.
“Rule 506”
means Rule 506 promulgated under Regulation D under the Securities Act or any successor provision.
“SEC Reports”
means (i) the Form 20-F filed by the Company, and (ii) each form, document, statement and report filed by the Company since September
20, 2019.
“Securities”
has the meaning specified in the preamble to this Agreement.
“Securities Act”
means the Securities Act of 1933, as amended (or any successor act), and the rules and regulations thereunder (or respective successors
thereto).
“Share Closing”
has the meaning specified in Section 1.1 of this Agreement.
“Share Closing Date”
has the meaning specified in Section 1.1 of this Agreement.
“Share Purchase
Price” has the meaning specified in Section 1.1 of this Agreement.
1.3
Other Definitional Provisions. All definitions contained in this Agreement are equally applicable to the singular and plural
forms of the terms defined. The words “hereof”, “herein” and “hereunder”
and words of similar import referring to this Agreement refer to this Agreement as a whole and not to any particular provision of this
Agreement.
| 2. | REPRESENTATIONS AND WARRANTIES OF THE INVESTOR. |
The Investor hereby represents
and warrants to the Company and agrees with the Company, that, as of the date hereof:
2.1
Enforceability. The Investor has the requisite power and authority to purchase the Securities to be purchased by him hereunder
and to execute, deliver and perform its obligations pursuant to this Agreement. This Agreement constitutes, upon execution and delivery
thereof, the Investor’s valid and legally binding obligation, enforceable in accordance with its terms, subject to (i) applicable
bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or other similar laws of general application relating to or affecting
the enforcement of creditors’ rights generally and (ii) general principles of equity.
2.2
Investor Status. At the time the Investor was offered the Securities, the Investor was and at the date hereof, is (i) an
“accredited investor” as defined in Rule 501 of Regulation D under the Securities Act and (ii) not formed or organized with
the specific purpose of making an investment in the Company. The Investor’s financial condition is such that he is able to bear
the risk of holding the Securities for an indefinite period of time and the risk of loss of his entire investment. The Investor has such
knowledge and experience in business and financial matters so as to enable it to understand the risks of and form an investment decision
with respect to his investment in the Securities.
2.3
Disqualification. The Investor represents that neither the Investor, nor any person or entity with whom the Investor shares
beneficial ownership of Company securities, is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i)
to (viii) under the Securities Act. Investor also agrees to notify the Company if Investor or any person or entity with whom Investor
or any person or entity with whom Investor shares beneficial ownership of Company securities becomes subject to such disqualifications
after the date hereof (so long as Investor or any such person beneficially owns any equity securities of the Company).
2.4
Purchase Entirely for Own Account. The Investor is acquiring the Securities for his own account and not with a view to,
or for sale in connection with, any distribution of the Securities in violation of the Securities Act. The Investor has no present agreement,
undertaking, arrangement, obligation or commitment providing for the disposition of the Securities.
2.5
Information. The Investor acknowledges that he has been provided with information regarding the business, operations and
financial condition of the Company and has, prior to the date hereof, been granted the opportunity to ask questions of and receive answers
from representatives of the Company, its officers, directors, employees and agents concerning the Company in order for the Investor to
make an informed decision with respect to his investment in the Securities. The Investor has sought such accounting, legal and tax advice
as well as language translation since this agreement is written in English as he deems appropriate in connection with his proposed investment
in the Securities.
2.6
Securities Not Registered in the United States. The Investor understands that the Securities have not been registered under
the Securities Act, by reason of their issuance by the Company in a transaction exempt from the registration requirements of the Securities
Act, and that the Securities must continue to be held by the Investor until a subsequent disposition thereof is registered under the Securities
Act, including pursuant to the Registration Statement, or is exempt from such registration.
2.7
Reliance on Exemptions. The Investor understands that the Securities are being offered and sold to him in reliance upon
specific exemptions from the registration requirements of U.S. federal and state securities laws and that the Company is relying upon
the truth and accuracy of the representations and warranties of the Investor set forth in this Section 2 in order to determine
the availability of such exemptions and the eligibility of the Investor to acquire the Securities.
2.8
Securities Ownership. The Investor’s investment in the Securities is not for the purpose of acquiring, directly or
indirectly, control of, and they have no intent to acquire or exercise control of, the Company.
2.9
Investor’s Financing. At the Closing, the Investor will have all funds necessary to pay to the Company the Share Purchase
Price for the Securities being purchased by the Investor hereby in immediately available funds.
2.10
Brokers. The Investor has not retained, utilized or been represented by any broker or finder in connection with the transactions
contemplated by this Agreement whose fees the Company would be required to pay.
2.11
No Governmental Review. The Investor understands that no Governmental Authority has passed on or made any recommendation
or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon
or endorsed the merits of the offering of the Securities.
2.12
No General Solicitation. The Investor is not purchasing the Securities as a result of any advertisement, article, notice
or other communication published in a newspaper or magazine or similar media or broadcast over television or radio, whether closed circuit,
or generally available, or any seminar, meeting or other conference whose attendees were invited by any general solicitation or general
advertising.
2.13
Reliance on Information. The Investor has, in connection with the Investor’s decision to purchase the Securities,
not relied upon any representations or other information (whether oral or written) other than as set forth in the representations and
warranties of the Company contained herein and in the SEC Reports, and the Investor has, with respect to all matters relating to this
Agreement and the offer and sale of the Securities, relied solely upon the advice of the Investor’s own counsel and has not relied
upon or consulted counsel of the Company.
| 3. | REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby represents and
warrants to the Investor and agrees with the Investor that, as of the date hereof: |
3.1
Organization, Good Standing and Qualification. The Company is duly organized, validly existing and in good standing under
the laws of the jurisdiction of its organization, with all requisite power and authority to carry on its business as now conducted. The
Company is not in violation of its certificate of incorporation, by-laws or other equivalent organizational or governing documents, except
where the violation would not, individually or in the aggregate, have a Material Adverse Effect.
3.2
Authorization; Consents. The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement and to issue and sell the Securities to the Investor in accordance with the terms hereof. All consents, approvals,
orders and authorizations required on the part of the Company in connection with the execution, delivery or performance of this Agreement
have been obtained or made, other than such consents, approvals, orders and authorizations the failure of which to make or obtain would
not have a Material Adverse Effect.
3.3
Enforcement. This Agreement has been duly executed and delivered by the Company. This Agreement constitutes the valid and
legally binding obligation of the Company, enforceable against it in accordance with its terms, subject to (i) applicable bankruptcy,
insolvency, fraudulent transfer, moratorium, reorganization or other similar laws of general application relating to or affecting the
enforcement of creditors’ rights generally, (ii) general principles of equity and (iii) with respect to the enforcement of any rights
to indemnity and contribution, federal and state securities laws and principles of public policy.
3.4
Disqualification. The Company is not disqualified from relying on Rule 506 for any of the reasons stated in Rule 506(d)
in connection with the issuance and sale of the Securities to the Investor.
3.5
Capitalization. The capitalization of the Company, including its authorized capital stock, the number of shares issued and
outstanding, the number of shares issuable and reserved for issuance pursuant to the Company’s equity plans and agreements and the
number of shares issuable and reserved for issuance pursuant to securities exercisable for, or convertible into or exchangeable for any
ADSs, is as set forth in the SEC Reports. Other than as contemplated by this Agreement and as described in the SEC Reports, there are
no options, warrants, calls, rights, commitments, preemptive rights, rights of first refusal or other agreements to which the Company
is a party or by which it is bound obligating the Company to issue, deliver, sell, repurchase or redeem, or cause to be issued, delivered,
sold, repurchased or redeemed, any shares of the capital stock of the Company or obligating the Company to grant, extend or enter into
any such option, warrant, call, right, commitment or agreement. No preemptive right, co-sale right, right of first refusal or other similar
right exists with respect to the Securities or the issuance and sale thereof. No further approval or authorization of any stockholder,
or the Board of Directors is required for the issuance and sale of the Securities.
3.6
Due Authorization; Valid Issuance. The Securities are duly authorized and, when issued in accordance with the terms of this
Agreement, will be duly and validly issued, fully paid and nonassessable, free of pre-emptive or similar rights and free and clear of
all liens, encumbrances and other restrictions (other than those arising under federal or state securities laws as a result of the private
placement contemplated hereby).
3.7
General Solicitation; No Integration. Neither the Company nor any of its Affiliates, nor any person acting on its or their
behalf, has engaged in a general solicitation or general advertising (within the meaning of Regulation D) of investors with respect to
offers or sales of the Securities.
3.8
Stockholder Consent. No consent or approval of the stockholders of the Company is required or necessary for the Company
to enter into this Agreement or to consummate the transactions contemplated hereby and thereby.
| 4. | OTHER AGREEMENTS OF THE PARTIES. |
4.1
Transfer Restrictions.
(a) The Investor covenants that
the Securities will only be disposed of pursuant to an effective registration statement under, and in compliance with the requirements
of, the Securities Act or pursuant to an available exemption from the registration requirements of the Securities Act, and in compliance
with any applicable state securities laws, provided that, the Investor shall not transfer any Securities or convert any Securities to
ADS of the Company except that the Investor (i) may transfer 50% Securities or convert such 50% Securities to ADS of the Company on or
after the 180th day after the Share Closing Date, and (ii) may transfer the remaining 50% Securities or convert such 50% Securities to
ADS on or after the first anniversary of the Share Closing Date. In connection with any transfer of Securities other than pursuant to
an effective registration statement or to the Company, the Company may require the transferor to provide to the Company an opinion of
counsel selected by the transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect
that such transfer does not require registration under the Securities Act.
(b) The Investor agrees to
the imprinting, so long as is required by this Section 4.1(b), of a legend on any certificate evidencing Securities
substantially to the following effect:
“THE SECURITIES REFERENCED
HEREIN HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”) AND
HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION
MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE U.S. SECURITIES ACT.”
5.1
Conditions to Investor’s Obligations at the Closings. The Investor’s obligations to effect the Closing, including
without limitation its obligation to purchase the Securities at Closing, are conditioned upon the fulfillment (or waiver by the Investor
in its sole and absolute discretion) of each of the following events as of the Closing Date:
| 5.1.1 | the representations and warranties of the Company set forth in this Agreement shall be true and correct
in all material respects as of the Closing Date as if made on such date (except that to the extent that any such representation or warranty
relates to a particular date, such representation or warranty shall be true and correct in all material respects as of that particular
date); |
5.2
Conditions to Company’s Obligations at the Closings. The Company’s obligations to effect the Closing with the
Investor are conditioned upon the fulfillment (or waiver by the Company in its sole and absolute discretion) of each of the following
events as of the Closing Date:
| 5.2.1 | the representations and warranties of the Investor set forth in this Agreement shall be true and correct
in all material respects as of the Closing Date as if made on such date (except that to the extent that any such representation or warranty
relates to a particular date, such representation or warranty shall be true and correct in all material respects as of that date); |
| 5.2.2 | the Investor or another person agreed by the Company shall have tendered to the Company the Share Purchase
Price for the Securities being purchased by it at the Closing by wire transfer of immediately available funds. |
6.1
Termination. This Agreement may be terminated by the Company or the Investor, by written notice to the other party, if the
Closings have not been consummated within five business days after effectiveness of this Agreement; provided that no such termination
will affect the right of any party to sue for any breach by the other party.
6.2
Liquidated Damages.
6.2.1
If (a) the Investor has completed its obligations under Sections 5.1.1 and 5.1.2, and has tendered the Share Purchase
Price as required in Section 5.2.2, and (b) the Company fails to complete the obligations set forth in Section 5.1, then
upon receipt of written or email request from the Investor, the Company shall promptly return to the Investor any cash deposit to the
Company Bank Account made by the investor within 5 business days; the Investor is entitle to a penalty payment by the company to the Investor
at the rate of 1% per day if the cash is not returned to the investor after the 5 business days post notification.
6.2.2
If (a) the Company has completed its obligations under Section 5.2.1 and has tendered the Securities as required in 5.1.2, and
(b) the Investor fails to complete the obligations set forth in Section 5.2 or otherwise fails to consummate the transaction, then the
Company shall have no obligation to issue the Securities.
The Company shall pay all expenses
incurred by the Investor enforcing of this Agreement including the Investor’s legal, litigation fees, court costs and expenses.
6.2.3
This Section 6.2 shall survive any termination or expiration of this Agreement.
6.3
Survival; Severability. The covenants and indemnities, agreements, representations and warranties made by the parties herein
shall survive the Closings, provided, however, that the representations and warranties set forth or made by the Investor herein will terminate
upon the final sale of the Securities. In the event that any provision of this Agreement becomes or is declared by a court of competent
jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided
that in such case the parties shall negotiate in good faith to replace such provision with a new provision which is not illegal, unenforceable
or void, as long as such new provision does not materially change the economic benefits of this Agreement to the parties.
6.4
Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
respective successors and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations
under this Agreement without the written consent of the other party.
6.5
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of the Company and the Investor will be entitled to seek specific performance under this Agreement. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing
sentence and hereby agrees to waive in any action for specific performance of any such obligation (other than in connection with any action
for temporary restraining order) the defense that a remedy at law would be adequate.
6.6
Governing Law; Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with,
the laws of the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the State of New York for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue
of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it
under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereby waives
all rights to a trial by jury.
6.7
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and
all of which together shall constitute one and the same instrument. This Agreement may be executed and delivered by facsimile transmission.
6.8
Headings. The headings used in this Agreement are used for convenience only and are not to be considered in construing or
interpreting this Agreement.
6.9
Notices. Any notice, demand or request required or permitted to be given by the Company or any Investor pursuant to the
terms of this Agreement shall be in writing and shall be deemed delivered (i) when delivered personally or by verifiable facsimile transmission,
unless such delivery is made on a day that is not a Business Day, in which case such delivery will be deemed to be made on the next succeeding
Business Day, (ii) on the next Business Day after timely delivery to an overnight courier and (iii) on the Business Day actually received
if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid), addressed as follows:
If to the Company:
Fresh2 Group Limited
Address: 650 5th AVE STE 2416
NEW YORK NY 10019
Email: shareholder@fresh2.co
Telephone: +1-9173976890
If to the Investor:
Danni Zhang
Address: 4310 Crescent 1404, Long Island
City New York 11101
Email: DZHANG20@PRATT.EDU
6.10
Fees and Expenses. The Company shall pay all expenses incurred incident to the negotiation, preparation, execution, delivery
and performance of this Agreement, including reasonable fees and expenses of the Investor’s legal advisers incurred on or prior
to the Closing Dates. The Company shall pay all stamp taxes and other taxes and duties levied in connection with the sale and issuance
of his Securities. Upon request by written or email notice from the Investor, the Company shall remove within 5 business days all the
legend of any certificate evidencing that the Security is registered, and all restriction written per section 4.1.a and 4.1.b removed;
the Company shall pay all expenses incurred to remove the legend and registered the Security.
6.11
Entire Agreement; Amendments. This Agreement constitutes the entire agreement between the parties with regard to the subject
matter hereof, superseding all prior agreements or understandings, whether written or oral, between or among the parties. Except as expressly
provided herein, neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company
and the Investor, and no provision hereof may be waived other than by a written instrument signed by the party against whom enforcement
of any such waiver is sought. Any waiver or consent shall be effective only in the specific instance and for the specific purpose for
which given.
[Signature Pages to Follow]
IN WITNESS WHEREOF, the undersigned
have duly executed this Securities Purchase Agreement as of the date first above written.
|
Fresh2 Group Limited |
|
|
|
|
By: |
|
|
Name: |
Haohan Xu |
|
Title: |
Chairperson and Chief Executive Officer |
|
Date: |
March 13, 2024 |
|
|
|
|
Investor |
|
|
|
|
Danni Zhang |
|
|
|
|
By: |
/s/ Danni Zhang |
10
v3.24.1
Cover
|
Dec. 08, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Dec. 08, 2023
|
Entity File Number |
001-39137
|
Entity Registrant Name |
Fresh2 Group Limited
|
Entity Central Index Key |
0001786511
|
Entity Tax Identification Number |
00-0000000
|
Entity Incorporation, State or Country Code |
D8
|
Entity Address, Address Line One |
650 5TH AVE STE 2416
|
Entity Address, City or Town |
NEW YORK
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10019-6108
|
City Area Code |
917
|
Local Phone Number |
397-6890
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
American depositary shares (each representing 20 Class A ordinary shares, par value US$0.01 per share) |
|
Title of 12(b) Security |
American depositary shares (each representing 20 Class A ordinary shares, par value US$0.01 per share)
|
Trading Symbol |
FRES
|
Security Exchange Name |
NASDAQ
|
Class A ordinary share, par value US$0.01 per share |
|
Title of 12(b) Security |
Class A ordinary share, par value US$0.01 per share
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=FRES_AmericanDepositarySharesEachRepresenting20ClassOrdinarySharesParValueUs0.01PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=FRES_ClassOrdinaryShareParValueUs0.01PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
AnPac Bio Medical Science (NASDAQ:ANPC)
過去 株価チャート
から 9 2024 まで 10 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
過去 株価チャート
から 10 2023 まで 10 2024